Industry News (Patents and Technology)

Priority in Ex Vivo Gene Therapy Cases To Be Determined

Published in Gene Therapy Weekly, February 26th, 1996

Somatix Therapy Corporation, Alameda, California, announced that the Patent and Trademark Office (PTO) has declared an interference between a pending patent application licensed to the company, a patent application of a second company, and a patent recently issued and licensed to Genetic Therapy, Inc., Gaithersburg, Maryland.

The U.S. patent, number 5,399,346, was issued on March 21, 1995, and lists as Inventors Drs. W. French Anderson, Michael Blaese, and Steven Rosenberg. When issued, its claims were widely interpreted as encompassing the entire field of ex vivo gene therapy.

The Somatix application involved in the interference is derived from...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1996-02-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry